approval · primary record
MEPOLIZUMAB
2 approval events · latest 2025-08-06
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2025-08-06 |
| Approval events | 2 |
| Brand | NUCALA |
| Sponsor | GLAXOSMITHKLINE |
| Route | SUBCUTANEOUS |
Approval history
2 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2025-08-06 | FDA | BLA | NUCALA | GLAXOSMITHKLINE | SUBCUTANEOUS |
| 2025-05-22 | FDA | BLA | NUCALA | GLAXOSMITHKLINE LLC | SUBCUTANEOUS LYOPHILIZED POWER |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:30:24.366Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:mepolizumab
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Mepolizumab · compound